Sangamo Therapeutics experienced a sharp rally in active trading Monday, with shares climbing approximately 33% to $0.18 after reaching an intraday high of $0.2156. The move comes just one day before the genomic-medicine company is set to exit the Nasdaq Capital Market and begin trading on the OTCQB Venture Market.
The transition, effective May 5, follows a delisting notice from Nasdaq due to Sangamo's failure to maintain the exchange's $1 minimum bid price requirement. According to a company filing, the stock traded below $1 for 30 consecutive trading days, triggering an initial warning in April 2025. After an additional compliance period, Sangamo received a formal delisting notice on April 28, 2026.
Nasdaq is scheduled to suspend trading in SGMO at the open on May 5. Sangamo has stated it will appeal the decision to a Nasdaq hearings panel. While the appeal could delay the official delisting process, it will not lift the trading suspension, according to the company's filing.
The company has secured approval to list on the OTCQB Venture Market, operated by OTC Markets Group, and intends to retain its SGMO ticker symbol. The OTCQB is designed for smaller and early-stage companies, but unlike Nasdaq, it does not qualify as a full exchange listing. This shift has drawn attention from investors, who are monitoring potential changes in liquidity, shareholder composition, and restrictions for funds that are prohibited from holding over-the-counter securities. Sangamo has maintained that the move should not materially impact its business or day-to-day operations.
Sangamo shares recovered some ground Monday after falling sharply on the delisting news. Data from the company's investor site shows the stock closed at $0.21 on April 27, slipped to $0.20 on April 28, then dropped to $0.13 on April 29 before ticking up to $0.14 on May 1. Trading volume picked up significantly once the OTCQB switch was announced.
Beyond the listing issue, Sangamo's drug pipeline remains a central focus. The company's lead candidate is isaralgagene civaparvovec (ST-920), an experimental one-time gene therapy for Fabry disease, which affects the kidneys, heart, nerves, and other organs. In March, Sangamo initiated a rolling Biologics License Application (BLA) with the U.S. Food and Drug Administration for ST-920, allowing the company to submit sections of the application as they are completed rather than waiting for the entire package.
Fabry disease faces established competition. Sanofi markets Fabrazyme, an enzyme-replacement therapy for confirmed patients, while Amicus Therapeutics offers Galafold, approved for specific adults with amenable GLA gene variants. Sangamo is also highlighting its foundational technology, with three abstracts accepted by the American Society of Gene & Cell Therapy for its annual meeting scheduled for May 11-15. The research spans neurology, zinc finger epigenetic regulation, and modular integrase technology. Chief Executive Sandy Macrae stated that advances in the neurology pipeline and the strength of the genome engineering platform will be prominently featured.
The broader gene therapy landscape remains uncertain. In late 2024, Pfizer terminated its hemophilia A gene therapy partnership with Sangamo, citing trial results, expert feedback, and what it described as tepid patient demand for an additional gene therapy targeting moderate to severe hemophilia A.
Sangamo continues to seek fresh capital and is evaluating options for its assets. The company has noted that it is in discussions regarding several potential business development deals but will only disclose specifics if binding agreements are reached. However, the core financial challenge persists: even with an OTCQB listing and a Nasdaq appeal in progress, Sangamo's significant financing gap remains unresolved. In March, the company flagged major risks, including capital shortages that could derail approval or commercialization of its candidates, no guarantee of securing a partner to bring ST-920 to market, and doubts about the durability of clinical benefits from trials.
For now, SGMO is in the hands of event-driven traders. The Fabry program, upcoming scientific updates, and potential deals all remain in play. But the immediate focus is clear: Nasdaq trading halts at the open on May 5, and Sangamo's next chapter begins on the OTCQB.
